Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, open-label, phase 1 study with a three-period, three-sequence, crossover design evaluating the effect of food (low and high fat) on the PK, safety, and tolerability of a single, oral dose of FCN-159

Next Previous
Trial Profile

A single-center, open-label, phase 1 study with a three-period, three-sequence, crossover design evaluating the effect of food (low and high fat) on the PK, safety, and tolerability of a single, oral dose of FCN-159

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luvometinib (Primary)
  • Indications Glioma; Histiocytosis; Malignant melanoma; Neurofibromatosis 1; Plexiform neurofibroma; Vascular disorders
  • Focus Pharmacodynamics

Most Recent Events

  • 13 Jan 2023 New trial record
  • 11 Jan 2023 Results published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top